Investigating a new oral treatment for intestinal fibrosis in Crohn's disease
Oral elafin formulation for intestinal fibrosis
This study is testing a new oral treatment using a protective peptide called elafin to help people with Crohn's disease who have intestinal fibrosis, with the hope of finding a better way to manage their symptoms and improve their quality of life.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11049016 on NIH RePORTER |
What this research studies
This research focuses on developing an oral formulation of elafin, a protective peptide, to treat intestinal fibrosis associated with Crohn's disease. The study aims to establish effective oral regimens using modified elafin in mouse models that mimic preexisting intestinal fibrosis. Researchers will explore how elafin works at the cellular level to inhibit collagen production and other fibrogenic processes. The ultimate goal is to provide a new therapeutic option that could improve the quality of life for patients suffering from this challenging condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Crohn's disease who are experiencing intestinal fibrosis.
Not a fit: Patients without Crohn's disease or those not experiencing intestinal fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel oral treatment that alleviates intestinal fibrosis, potentially reducing the need for surgical interventions.
How similar studies have performed: While the specific approach of using elafin for intestinal fibrosis is novel, similar studies have shown promise in using peptides for treating fibrotic conditions.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Koon, Hon Wai — University of California Los Angeles
- Study coordinator: Koon, Hon Wai
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.